

Special Issue

Vaccines Against Sexually Transmitted Diseases

Message from the Guest Editors

Sexually transmitted infections (STI) have major adverse and though preventable impacts on reproductive health, perinatal morbidity, several common cancers, and HIV. According to the World Health Organization, more than 1 million STIs are acquired every day

([https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)))

[sheets/detail/sexually-transmitted-infections-\(stis\)\)](https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis))),

while data from the Centers for Disease Control indicates that STI rates have increased for the fifth consecutive year (STD Surveillance, 2018. Atlanta, GA: US Department of Health and Human Services, October 2019). Aggressive control efforts (i.e., counseling and behavioral interventions, barrier technologies such as condom use, rapid diagnosis, screening, and treatment programs, and partner notification) alone have not reduced STI prevalence. Moreover, the introduction of highly effective HIV prevention tools is correlated with increases in STI in some populations at risk for HIV, and antimicrobial resistance continues to threaten STI control.

Guest Editors

Prof. Dr. Nicholas Van Wagoner

The University of Alabama at Birmingham, Birmingham, United States

Prof. Dr. Edward W. Hook III

Medicine/Infectious Diseases, The University of Alabama at Birmingham, Birmingham, AL 35233, USA

Deadline for manuscript submissions

closed (31 October 2020)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/43231

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).